Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities
The objective of the present Post Marketing Surveillance Study (PMS) study is to evaluate safety and effectiveness of tiotropium bromide (Spiriva®) 18 µg once daily in 5,000 patients with COPD of varying severities over 8 weeks.
Pulmonary Disease, Chronic Obstructive
|Study Design:||Time Perspective: Prospective|
|Official Title:||Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities|
- Patient Global Assessment of Chronic Obstructive Pulmonary Disease (COPD) Symptom at Visit 1 and Visit 3 (Number of Patients Whose Assessment Were Excellent and Good) [ Time Frame: 0 weeks (Visit 1) and 8 weeks (Visit 3) ]
The score is evaluated according to a 8-point scale(poor: 1-2, fair: 3-4, good: 5-6, excellent: 7-8; 1 point meaning most COPD-associated symptoms and signs and 8 point meaning least).
Represents number of participants who score ""good"" and ""excellent"" at visit 1 (0 weeks) and visit 3 (8 weeks)
|Study Start Date:||May 2006|
|Primary Completion Date:||February 2008 (Final data collection date for primary outcome measure)|